ProShare Advisors
MACK

ProShare Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

ProShare Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,081
Closed -$98K – 1436
2017
Q2 		$98K Sell
10,081
-552
-5% -$11.3K ﹤0.01% 1401
2017
Q1 		$258K Sell
10,633
-2,742
-21% -$68.6K ﹤0.01% 1315
2016
Q4 		$429K Buy
13,375
+1,493
+13% +$63.7K ﹤0.01% 1155
2016
Q3 		$594K Sell
11,882
-2,100
-15% -$87.2K 0.01% 884
2016
Q2 		$593K Buy
13,982
+1,265
+10% +$68.9K 0.01% 896
2016
Q1 		$837K Sell
12,717
-1,235
-9% -$64.5K 0.01% 772
2015
Q4 		$867K Buy
13,952
+1,817
+15% +$128K 0.01% 803
2015
Q3 		$813K Sell
12,135
-803
-6% -$65.5K 0.01% 744
2015
Q2 		$1.26M Sell
12,938
-424
-3% -$40.3K 0.02% 668
2015
Q1 		$1.25M Buy
13,362
+1,773
+15% +$151K 0.01% 737
2014
Q4 		$1.03M Sell
11,589
-214
-2% -$15.6K 0.01% 834
2014
Q3 		$815K Sell
11,803
-2,253
-16% -$120K 0.01% 1147
2014
Q2 		$806K Sell
14,056
-8,355
-37% -$424K 0.01% 1268
2014
Q1 		$889K Buy
22,411
+15,787
+238% +$676K 0.01% 1398
2013
Q4 		$278K Sell
6,624
-5,697
-46% -$165K ﹤0.01% 1185
2013
Q3 		$368K Buy
12,321
+8,735
+244% +$306K 0.01% 1730
2013
Q2 		$190K Buy
+3,586
New +$157K ﹤0.01% 2061

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ProShare Advisors's MACK Position: Q3 2017 in Review

ProShare Advisors sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 10,081 shares — an estimated $98K sold.

ProShare Advisors first reported a position in MACK in Q2 2013 and held it in 17 quarters. The position peaked at $1.26M in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • ProShare Advisors reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • ProShare Advisors sold 10,081 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $98K.
  • ProShare Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 17 quarters.
  • ProShare Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $1.26M in Q2 2015.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on ProShare Advisors's 13F filing for Q3 2017, filed 13 Nov 2017.